Hims & Hers Health, Inc.

NYSE:HIMS Stock Report

Market Cap: US$6.3b

Hims & Hers Health Past Earnings Performance

Past criteria checks 4/6

Hims & Hers Health has been growing earnings at an average annual rate of 37.9%, while the Healthcare industry saw earnings growing at 2.6% annually. Revenues have been growing at an average rate of 49.3% per year. Hims & Hers Health's return on equity is 26.4%, and it has net margins of 8.5%.

Key information

37.9%

Earnings growth rate

57.8%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate49.3%
Return on equity26.4%
Net Margin8.5%
Next Earnings Update05 May 2025

Recent past performance updates

Recent updates

Hims & Hers Health: GLP-1 Deals De-Risk The Story

Apr 29

Hims & Hers: Look Past Near-Term GLP-1 Risks, This Is A Great Dip To Buy

Apr 23

With A 29% Price Drop For Hims & Hers Health, Inc. (NYSE:HIMS) You'll Still Get What You Pay For

Mar 24
With A 29% Price Drop For Hims & Hers Health, Inc. (NYSE:HIMS) You'll Still Get What You Pay For

Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There

Mar 20

Hims & Hers' Fall From Grace Is Warranted - Still No Margin Of Safety

Mar 03

Hims & Hers: Why This Q4 Earnings Dip Is A Buying Opportunity

Feb 25

Hims & Hers Q4 Preview: Is The Super Bowl Ad Worth $5B In Market Cap? (Rating Downgrade)

Feb 19

Hims & Hers Health: Explosive Growth Potential Ahead

Feb 11

Market Participants Recognise Hims & Hers Health, Inc.'s (NYSE:HIMS) Revenues Pushing Shares 46% Higher

Feb 04
Market Participants Recognise Hims & Hers Health, Inc.'s (NYSE:HIMS) Revenues Pushing Shares 46% Higher

Hims & Hers: Potential Risks Ahead, But Shorting May Be Premature

Jan 29

Hims & Hers Health: The Market Is Likely Wrong

Jan 19

Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns

Jan 09

Hims & Hers: Ready For Liftoff In 2025

Jan 02

Hims & Hers: FDA Ruling May Close Compounded GLP-1 Drug 'Loophole', It Was Fun While It Lasted

Dec 19

Hims & Hers: Look At What Matters Most

Dec 12

Hims & Hers: The Show Must Go On

Dec 05

Hims & Hers: Driving Growth In Wellness

Nov 29

Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 44% Share Price Surge

Nov 26
Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 44% Share Price Surge

Hims & Hers Health: The Amazon Curse Is Being Overstated

Nov 15

Hims & Hers: A Lot More Than Just GLP-1, And It's Proving Its Ability To Grow

Nov 05

HIMS: GLP-1 Is Just The Beginning

Oct 17

Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward

Oct 03

Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce

Oct 01
Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce

Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now

Sep 24
author-image

Expanding Into Personalized Weight Management And AI Integration Spurs Market Leadership

Sep 05 Expansion into weight management and GLP-1 compounds addresses a massive potential market, suggesting diversification and possible revenue growth.

Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)

Aug 27

Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade

Aug 20

Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Aug 11
Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump

Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage

Aug 07

Hims & Hers: The Thesis Goes Far Beyond GLP-1

Jul 18

Hims & Hers: Buy The Dip To Catch The Next Rip

Jun 24

Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Jun 19
Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge

Hims & Hers: The Undervalued Gem Poised For Growth

Jun 18

Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable

Jun 10

Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31
Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment

Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead

May 21

Revenue & Expenses Breakdown

How Hims & Hers Health makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:HIMS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 241,4771261,02879
30 Sep 241,24210189368
30 Jun 241,0671880260
31 Mar 24959-274353
31 Dec 23872-2469348
30 Sep 23793-3663943
30 Jun 23711-4758139
31 Mar 23616-5951434
31 Dec 22527-6644629
30 Sep 22444-8638126
30 Jun 22374-8332435
31 Mar 22321-7328128
31 Dec 21272-10828922
30 Sep 21229-8225017
30 Jun 21196-722170
31 Mar 21171-631860
31 Dec 20149-1811311
30 Sep 20132-251170
30 Jun 20112-381140
31 Mar 2095-581170
31 Dec 1983-721190
31 Dec 1827-75840

Quality Earnings: HIMS has high quality earnings.

Growing Profit Margin: HIMS became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: HIMS has become profitable over the past 5 years, growing earnings by 37.9% per year.

Accelerating Growth: HIMS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: HIMS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (15.1%).

Return on Equity

High ROE: HIMS's Return on Equity (26.4%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/29 15:50
End of Day Share Price 2025/04/29 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hims & Hers Health, Inc. is covered by 20 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vikram KesavabhotlaBaird
Allen LutzBofA Global Research
Allen LutzBofA Global Research